{"nctId":"NCT00880191","briefTitle":"Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy","startDateStruct":{"date":"2009-04"},"conditions":["Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific"],"count":430,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Drug: dexamethasone","Drug: gabapentin"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Drug: dexamethasone","Other: placebo"]}],"interventions":[{"name":"dexamethasone","otherNames":[]},{"name":"gabapentin","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Scheduled to receive highly emetogenic chemotherapy\n\n  * May be scheduled to receive prophylactic treatment for acute nausea and vomiting with a 5HT3 antagonist and dexamethasone 20 mg on day 1 of chemotherapy treatment\n  * May be scheduled to receive multiple day chemotherapy regimens as long as the chemotherapy drugs given on the subsequent days have mild or no emetogenic potential\n* Chemotherapy schedules must allow at least 7 days rest between courses involving administration of highly emetogenic chemotherapy\n* No primary CNS malignancy and/or CNS metastasis\n\nPATIENT CHARACTERISTICS:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Life expectancy ≥ 3 months\n* Creatinine ≤ 1.5 times upper limit of normal within the past 30 days\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Ability to complete questionnaire(s) by his/herself or with assistance\n* Able to swallow pills\n* No epilepsy or seizure history\n* No gastrointestinal obstruction, active peptic ulcer disease, or uncontrolled heartburn\n* No history of nausea and/or vomiting related to any kind of chemotherapy\n* No nausea or vomiting within the past 3 days\n* No history of allergic or other adverse reaction to gabapentin or pregabalin\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No prior moderate or highly emetogenic chemotherapy\n* No prior or concurrent aprepitant or any other NK-1 receptor antagonist\n* At least 1 months since prior and no concurrent gabapentin, pregabalin, or other anticonvulsants\n* At least 7 days since prior and no concurrent pelvic or abdominal radiotherapy\n* At least 3 days since prior antiemetics\n* No concurrent or planned use of lorazepam, diphenhydramine, eszopiclone, and/or dronabinol during the 6 days of this study, except for treatment of breakthrough nausea and vomiting","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Comparison of Percentage of Complete Responders","description":"Complete response being defined as no emetic episodes and no use of rescue therapy for days 2 through 6. If a patient does not complete the study or does not provide complete data, they will be assumed to be a non-responder.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"59.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"40.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response","description":"The primary analysis described above was repeated using a slightly different alternate definition of complete response: no emetic episodes, no more than a mean of 2.5 on the nausea numeric analogue scale (0 - 10 (As bad as it could be)), and no rescue agents.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"39.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Percentages of Complete Responders on Day 1, vs. Days 1 Through 6 vs. Days 2 Through 6.","description":"The percentages of complete responders on day 1, vs. days 1 through 6 vs. days 2 through 6 will be compared between arms. Complete response being defined as no emetic episodes and no use of rescue therapy. If a patient does not complete the study or does not provide complete data, they will be assumed to be a non-responder.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"33.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"66.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Percentage of Patients Experiencing Emetic Episodes and the Percentage Needing Rescue Agents","description":"The percentage of patients experiencing emetic episodes and the percentage needing rescue agents was compared between groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Sum of the Daily Distress Questions as Well as the Individual Daily Responses","description":"The sum of the daily distress questions as well as the individual daily responses from the Nausea and Vomiting Diary (NVD) on a 0-10 scale (Lower score is better) will be compared.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.3"},{"groupId":"OG001","value":"1.2","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.9"},{"groupId":"OG001","value":"1.1","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.9"},{"groupId":"OG001","value":"1.2","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.6"},{"groupId":"OG001","value":"1.1","spread":"1.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.9"},{"groupId":"OG001","value":"1.1","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.8"},{"groupId":"OG001","value":"0.9","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"8.0"},{"groupId":"OG001","value":"6.4","spread":"8.9"}]}]}]},{"type":"SECONDARY","title":"Level of Satisfaction for the Control of Nausea.","description":"Level of satisfaction for the control of nausea with the mean severity of nausea over the six days in the diary (on a 0 - 10 scale, higher the better) as well as the nausea subscale on the Functional Living Index - Emesis (FLIE) questionnaire ( 1-7 scale, lower the better)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"2.8"},{"groupId":"OG001","value":"8.1","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.0"},{"groupId":"OG001","value":"2.9","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Comparison of Daily Complete Response Endpoints","description":"Daily complete response is defined as no emetic episodes and no use of rescue therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":null},{"groupId":"OG001","value":"33.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.6","spread":null},{"groupId":"OG001","value":"66.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null},{"groupId":"OG001","value":"30.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":null},{"groupId":"OG001","value":"69.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9","spread":null},{"groupId":"OG001","value":"34.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"68.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":207},"commonTop":["Dizziness","Edema limbs","Ataxia","Depressed level of consciousness","Localized edema"]}}}